Skip to main content

Table 3 Effects of liguzinediol on hemodynamic parameters in MI rats

From: The protective effects of liguzinediol on congestive heart failure induced by myocardial infarction and its relative mechanism

Group

Dose (mg/kg)

LVSP (mmHg)

LVEDP (mmHg)

+dp/dtmax (mmHg/s)

−dp/dtmax (mmHg/s)

SBP (mmHg)

DBP (mmHg)

MAP (mmHg)

Sham

121.52 ± 11.58

12.80 ± 4.36

5486.62 ± 1274.77

− 4514.28 ± 1206.89

127.43 ± 13.73

101.40 ± 12.91

110.08 ± 12.24

MI

92.20 ± 9.14**

24.62 ± 11.53**

2879.57 ± 699**

− 2602.23 ± 709.79**

94.94 ± 14.45**

68.32 ± 9.91**

77.19 ± 10.94**

Captopril

10

117.70 ± 10.11##

11.07 ± 5.43##

5492.85 ± 1056.12##

− 4690.98 ± 407.66##

112.86 ± 14.92#*

83.65 ± 14.24#**

93.38 ± 13.06##**

Digoxin

0.032

107.94 ± 10.11##**

12.82 ± 4.35##

4334.41 ± 805.68##*

− 3688.32 ± 679.12##

117.25 ± 14.03##

89.02 ± 14.92##

98.43 ± 13.30##

Liguzinediol

5

112.95 ± 7.67##

14.50 ± 5.08#

4716.70 ± 761.77##

− 3902.99 ± 593.81##

117.29 ± 13.67##

86.93 ± 12.69##*

97.05 ± 12.52##*

10

116.26 ± 12.91##

13.77 ± 4.13#

4870.57 ± 839.12##

− 4052.40 ± 914.03##

119.43 ± 13.13##

89.17 ± 11.07##*

99.26 ± 11.34##

20

119.48 ± 7.28##

13.47 ± 5.15#

5205.27 ± 968.84##

− 4408.84 ± 704.99##

123.03 ± 14.78##

93.47 ± 11.70##

103.32 ± 12.46##

  1. Sham, sham-operated; MI, myocardial infarction; LVSP, LV systolic pressure; LVEDP, LV end-diastolic pressure; +dp/dtmax, maximal rate of the increase of LV pressure; −dp/dtmax, maximal rate of the decrease of LV pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean artery pressure
  2. Data are shown as the mean ± SD (n = 10). *P < 0.05, **P < 0.01, compared to Sham group; #P < 0.05, ##P < 0.01, compared to MI group